Good but INCOMPLETE list. They left off KPTI, which I just heard about today -- they're repurposing their successful multiple myeloma drug, running a clinical trial, expect results in 3 months.

Quote:

---

Karyopharm Therapeutics Inc. (KPTI) is planning to explore the potential of its approved multiple myeloma drug Selinexor, marketed as XPOVIO, in hospitalized patients with severe COVID-19.

Selinexor is an oral, selective inhibitor of nuclear export (SINE) compound which blocks the cellular protein XPO1. In addition to its roles in cancer, XPO1 also has a role in viral replication.

SINE compounds have been shown to disrupt the replication of multiple viruses in vitro and in vivo. In particular, SINE compounds have recently been identified as having the potential to interfere with key host protein interactions with SARS-CoV-2, the virus that causes COVID-19, noted the Company.

The Company is planning to initiate a global randomized clinical trial of Selinexor to treat patients with COVID-19. The proposed clinical trial to treat hospitalized patients with COVID-19 would be the first study of an XPO1 inhibitor in patients with severe viral infections.

https://markets.businessinsider.com/news/stoc...74280?op=1

---